VISION CARE IN PAPHOS
Intravitreal injection care begins with retinal assessment, OCT imaging, visual acuity measurement, and review of the underlying diagnosis. Treatment is planned from the clinical findings rather than from symptoms alone, and follow-up is structured around OCT findings, vision, and treatment response.
Assessment starts with the diagnosis and the reason injections are being considered, such as wet AMD, diabetic macular oedema, or macular oedema from retinal vein occlusion.
The visit typically includes visual acuity measurement, retinal examination, OCT imaging, and comparison with previous findings where available. This establishes whether there is active fluid, swelling, bleeding, or structural change affecting the macula.
OCT provides a cross-sectional view of the macula and shows whether fluid is present within or under the retina. It also helps document retinal thickness, structural change, and response to previous treatment.
OCT findings are interpreted together with vision and examination findings. This is important because symptoms alone do not always reflect the degree of retinal activity.
OCT provides a detailed cross-sectional view of the retina and is central to modern retinal care. Imaging supports diagnosis, establishes a baseline, and allows precise comparison over time.
In injection care, OCT is used to document whether retinal fluid is improving, recurring, or stable, alongside visual acuity and clinical findings. This supports treatment planning and follow-up. More detail is available on the Technology & Diagnostics page.
Visual acuity is measured because the aim of treatment is not only to improve an image on OCT, but to protect useful central vision. Vision results are interpreted alongside OCT findings and the patient's day-to-day visual function.
In some cases the OCT may improve before vision changes significantly; in others, vision may be limited by longer-standing retinal damage. This is why treatment response is assessed using both imaging and visual function.
Intravitreal injections deliver medication inside the eye to treat conditions affecting the macula and retina. Planning is based on symptoms, examination findings, and OCT results.
Injections are used when there is retinal fluid, bleeding risk, or active disease that threatens central vision. The decision is individualised and guided by imaging and clinical response.
Anti-VEGF medications reduce abnormal blood vessel leakage and swelling in the retina. They are commonly used for wet AMD and other retinal vascular conditions.
In selected situations, other medications including steroid-based treatments may be considered. Retinal laser photocoagulation may also be recommended as part of a broader management plan.
Injection treatment and follow-up are planned according to the diagnosis, OCT findings, visual function, and clinical response. The practice documents the clinical information needed for ongoing care.
Mild irritation, tearing, light sensitivity, or a small red spot on the eye are normal and usually resolve quickly. Avoid rubbing the eye and swimming for a short period after treatment.
Intravitreal injections are common and generally safe when performed with sterile technique. Rare risks include infection inside the eye (endophthalmitis), retinal tear or detachment, bleeding, or significant inflammation.
Retinal care
Detailed information about dry AMD monitoring and wet AMD treatment with intravitreal injections.
Assessment of diabetic retinopathy and macular oedema, including when injection therapy may be appropriate.
Evaluation of branch and central retinal vein occlusion, including OCT monitoring and treatment of macular oedema.
OCT, retinal imaging, and visual acuity measurement support treatment decisions and follow-up planning.
Most patients find the injection much less uncomfortable than expected. The eye is numbed beforehand, and the injection itself takes only a few seconds. Some patients feel brief pressure but rarely significant pain.
This depends on the diagnosis, OCT findings, visual function, and clinical response. At follow-up, the practice documents the information needed to support ongoing treatment decisions.
Vision may be slightly blurred for several hours after treatment, particularly if dilating drops were used. Most patients prefer to arrange transport for the day of the injection.